MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
3.950
-0.010
-0.25%
Opening 12:14 05/15 EDT
OPEN
3.880
PREV CLOSE
3.960
HIGH
4.050
LOW
3.853
VOLUME
9.77K
TURNOVER
--
52 WEEK HIGH
43.65
52 WEEK LOW
2.750
MARKET CAP
37.06M
P/E (TTM)
-2.4756
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)
TipRanks · 2d ago
Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)
TipRanks · 4d ago
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD)
TipRanks · 4d ago
Weekly Report: what happened at TVRD last week (0504-0508)?
Weekly Report · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Impedimed Limited (OtherIPDQF), Eli Lilly & Co (LLY) and Tvardi Therapeutics (TVRD)
TipRanks · 4d ago
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
TipRanks · 05/08 11:14
Tvardi Therapeutics Q1 net loss narrows
Reuters · 05/08 11:11
Tvardi Therapeutics Q1 EPS $(0.73) Beats $(0.74) Estimate
Benzinga · 05/08 11:11
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.